STAT6 and cancer: Although in this study it could not be ruled out that STAT6-dependent effects other than PD-L2 upregulation also played a role, these results indicate that we may in fact already be targeting PD-L2 in cancer patients with one of the clinically most widely used groups of chemotherapeutics [76].